Cytokinetics (CYTK) Interest Expenses (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Interest Expenses of $1.6 million for Q1 2026, down 83.57% year-over-year from $9.6 million in Q1 2025, and up 165.9% quarter-over-quarter from -$2.4 million in Q4 2025.
Cytokinetics (CYTK) Interest Expenses (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Interest Expenses for 16 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 83.57% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $19.9 million (down 51.23% YoY), while the FY2025 annual figure was $305.4 million, down 57.16% from the prior year.
- Interest Expenses rose to $1.6 million in Q1 2026 per CYTK's latest filing, from -$2.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $22.1 million in Q3 2025 and bottomed at -$10.8 million in Q4 2023.
- Historically, Interest Expenses has averaged $7.3 million across 5 years, with a median of $7.1 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 190.24% — and 2023, when it plunged 178.27%.
- Cytokinetics' Interest Expenses stood at $13.9 million in 2022, then slumped by 178.27% to -$10.8 million in 2023, then jumped by 187.76% to $9.5 million in 2024, then plunged by 125.27% to -$2.4 million in 2025, then surged by 165.9% to $1.6 million in 2026.
- Business Quant data shows CYTK's Interest Expenses at $1.6 million in Q1 2026, -$2.4 million in Q4 2025, and $22.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.08 Mn |
| Jun 30, 2026 | 4.08 Mn |
| Mar 31, 2026 | 1.59 Mn |
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Dec 31, 2025 | -2.41 Mn |
| Sep 30, 2025 | 22.14 Mn |
| Sep 30, 2025 | 22.14 Mn |
| Jun 30, 2025 | 11.08 Mn |
| Jun 30, 2025 | 11.08 Mn |
| Mar 31, 2025 | 9.65 Mn |
| Mar 31, 2025 | 9.65 Mn |
| Dec 31, 2024 | 9.52 Mn |
| Dec 31, 2024 | 9.52 Mn |
| Sep 30, 2024 | 8.93 Mn |
| Sep 30, 2024 | 8.93 Mn |
| Jun 30, 2024 | 12.73 Mn |
| Jun 30, 2024 | 12.73 Mn |
| Mar 31, 2024 | 10.21 Mn |
| Mar 31, 2024 | 10.21 Mn |